Ozanimod

Ozanimod
Systematic (IUPAC) name


5-(3-{(1S)-1-[(2-Hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile
Clinical data
Legal status	Investigational
Identifiers
CAS Number	1306760-87-1
PubChem	CID 52938427
ChemSpider	34979946
Synonyms	RPC1063
Chemical data
Formula	C₂₃H₂₄N₄O₃
Molar mass	404.46 g/mol
SMILES CC(C)Oc1ccc(cc1C#N)c2nc(no2)c3cccc4c3CC[C@@H]4NCCO
InChI InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1 Key:XRVDGNKRPOAQTN-FQEVSTJZSA-N

Ozanimod is an experimental drug for the treatment of multiple sclerosis and ulcerative colitis.^[1] It is an immunotherapy that modulates the sphingosine-1-phosphate 1 receptor.^[2]

References

↑ "Receptos Announces Positive Results for Ulcerative Colitis Therapy in Maintenance Period of Phase 2 Trial". Apr 22, 2015.
↑ "Safety and Tolerability of Orally Administered RPC1063, a Novel S1P1 Receptor Modulator, in Healthy Adult Volunteers, Results of a Phase 1 Study". Neurology 80 (Meeting Abstracts 1): P01.178. February 12, 2013.

This article is issued from Wikipedia - version of the Thursday, January 21, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.